SCM
VERV

Sterling Capital Management’s Verve Therapeutics VERV Stock Holding History

Sterling Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,904
Closed -$21.4K – 3291
2025
Q2 		$21.4K Buy
1,904
+678
+55% +$3.87K ﹤0.01% 1776
2025
Q1 		$5.6K Sell
1,226
-1,050
-46% -$7.03K ﹤0.01% 2107
2024
Q4 		$12.8K Buy
2,276
+2,026
+810% +$11.4K ﹤0.01% 2051
2024
Q3 		$1.21K Buy
+250
New +$1.45K ﹤0.01% 2433

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Sterling Capital Management's VERV Position: Q3 2025 in Review

Sterling Capital Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 1,904 shares — an estimated $21.4K sold.

Sterling Capital Management first reported a position in VERV in Q3 2024 and held it in 4 quarters. The position peaked at $21.4K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Sterling Capital Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sterling Capital Management sold 1,904 Verve Therapeutics shares in Q3 2025, an estimated $21.4K.
  • Sterling Capital Management first reported a position in Verve Therapeutics in Q3 2024 and held it in 4 quarters.
  • Sterling Capital Management's Verve Therapeutics position peaked at $21.4K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Sterling Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.